Page last updated: 2024-10-31

n(1),n(11)-diethylnorspermine and Disease Exacerbation

n(1),n(11)-diethylnorspermine has been researched along with Disease Exacerbation in 1 studies

N(1),N(11)-diethylnorspermine: structure given in first source

Research Excerpts

ExcerptRelevanceReference
" Polyamine analogs down-regulate ornithine decarboxylase, induce spermidine/spermine N1-acetyltransferase, deplete natural polyamine pools, inhibit growth, and induce programmed cell death in breast cancer models."9.10A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer. ( Armstrong, DK; Bender, JF; Carducci, MK; Casero, RA; Davidson, NE; Fetting, JH; Riley, CD; Wolff, AC, 2003)
" Polyamine analogs down-regulate ornithine decarboxylase, induce spermidine/spermine N1-acetyltransferase, deplete natural polyamine pools, inhibit growth, and induce programmed cell death in breast cancer models."5.10A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer. ( Armstrong, DK; Bender, JF; Carducci, MK; Casero, RA; Davidson, NE; Fetting, JH; Riley, CD; Wolff, AC, 2003)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wolff, AC1
Armstrong, DK1
Fetting, JH1
Carducci, MK1
Riley, CD1
Bender, JF1
Casero, RA1
Davidson, NE1

Trials

1 trial available for n(1),n(11)-diethylnorspermine and Disease Exacerbation

ArticleYear
A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Dec-01, Volume: 9, Issue:16 Pt 1

    Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Drug Administration Sched

2003